Optimark and Lower extremity mass - a phase IV clinical study of FDA data

Summary:

Lower extremity mass is reported as a side effect among people who take Optimark (gadoversetamide), especially for people who are female, 50-59 old, also take Omniscan, and have Infection.

The phase IV clinical study analyzes which people have Lower extremity mass when taking Optimark. It is created by eHealthMe based on reports of 3,054 people who have side effects when taking Optimark from the FDA, and is updated regularly.

What is Optimark?

Optimark has active ingredients of gadoversetamide. eHealthMe is studying from 3,055 Optimark users. Check the latest studies of Optimark.

What is Lower extremity mass?

Lower extremity mass (mass in lower legs) is found to be associated with 161 drugs and 298 conditions by eHealthMe. Check the latest studies of Lower extremity mass.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 29, 2026

3,054 people reported to have side effects when taking Optimark.
Among them, 11 people (0.36%) have Lower extremity mass.

Could Optimark cause Lower extremity mass?

Among these 11 people:

What is the gender of people who have Lower extremity mass when taking Optimark? *

female: 80 %
male: 20 %

What is the age of people who have Lower extremity mass when taking Optimark? *

What are other drugs people take besides Optimark? *

What are other side effects people have besides Lower extremity mass? *

Nephrogenic Systemic Fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease): 11 people, 100.00%
Rashes (redness): 10 people, 90.91%
General Physical Health Deterioration (weak health status): 9 people, 81.82%
Skin Discoloration: 9 people, 81.82%
Pain: 8 people, 72.73%
Injury: 8 people, 72.73%
Stress And Anxiety: 8 people, 72.73%
Emotional Distress: 8 people, 72.73%
Oedema Peripheral (superficial swelling): 6 people, 54.55%
Mobility Decreased (ability to move is reduced): 6 people, 54.55%

What are the existing conditions these people have? *

Pain: 1 person, 9.09%
Muscle Spasms (muscle contraction): 1 person, 9.09%
Infection: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Optimark and have Lower extremity mass?

- Check whether Lower extremity mass is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Optimark:

Optimark (3,055 reports)

Browse all side effects of Optimark:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Lower extremity mass:

Lower extremity mass (161 drugs)

Browse all the conditions that are associated with Lower extremity mass:

Lower extremity mass (298 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on gadoversetamide (the active ingredients of Optimark) and Optimark (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.